Document is current
Any future updates will be listed below
-
Authors
Miyazaki, Kikuko https://orcid.org/0000-0003-0883-1506
Suzukamo, Yoshimi
Ikenaga, Masayuki
Ohsumi, Shozo
Saito, Mari
Satomi, Eriko
Shimozuma, Kojiro
Nakayama, Takeo
- License Information
-
More Information
Article History
Received: 3 November 2023
Accepted: 23 February 2025
First Online: 19 March 2025
Declarations
:
: The Ethics Committees of Kyoto University Graduate School and Faculty of Medicine (E-446) approved the study, as did the institutional review boards of each participating facility. Patients were given written and verbal requests for consent to participate in the study.
: It was obtained when consent was obtained to participate in the study.
: Kikuko Miyazaki reports personal fees from Bayer Yakuhin Ltd. and Intage Healthcare Inc. Yoshimi Suzukamo reports personal fees from Bayer Yakuhin Ltd., Pfizer Japan Inc., Otsuka Holdings Co. Ltd., ASKA Pharmaceutical Co. Ltd., GlaxoSmithKline K.K., Qualitest Inc., and Intage Healthcare Inc. Shozo Ohsumi reports personal fees from Astra Zeneca K.K. Takeo Nakayama reports COI as follows: Research grants from I&H Co., Ltd., Cocokarafine Co., Ltd., and Konica Minolta Inc.;consulting fees from Otsuka Pharmaceutical;Honoraria from Pfizer Japan Inc., MSD K.K., Chugai Pharamaceutical Co., Takeda Pharmaceutical Co., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Maruho Co., Ltd., Mitsubishi Tanabe Pharma Co, Novartis Pharma K.K., Allergan Japan K.K., Maruho Co., Ltd., Novo Nordisk Pharma Ltd.,TOA EIYO Ltd., Dentsu co., ONO PHARMACEUTICAL CO., LTD., GSK plc, Alexion Pharmaceuticals Inc., Cannon Medical Systems Co.Stock options from Bon Bon Inc.; Donations from Cancer Scan and YUYAMA co.
